78 related articles for article (PubMed ID: 16504501)
1. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
Mulvihill MJ; Kan JL; Beck P; Bittner M; Cesario C; Cooke A; Keane DM; Nigro AI; Nillson C; Smith V; Srebernak M; Sun FL; Vrkljan M; Winski SL; Castelhano AL; Emerson D; Gibson N
Bioorg Med Chem Lett; 2005 Mar; 15(6):1669-73. PubMed ID: 15745819
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
[TBL] [Abstract][Full Text] [Related]
4. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.
McCaffery P; Simons C
Curr Pharm Des; 2007; 13(29):3020-37. PubMed ID: 17979744
[TBL] [Abstract][Full Text] [Related]
5. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
6. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
8. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
9. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids.
Njar VC; Nnane IP; Brodie AM
Bioorg Med Chem Lett; 2000 Sep; 10(17):1905-8. PubMed ID: 10987414
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.
Gomaa MS; Bridgens CE; Aboraia AS; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Apr; 54(8):2778-91. PubMed ID: 21428449
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
15. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.
Freyne E; Raeymaekers A; Venet M; Sanz G; Wouters W; De Coster R; Wauwe JV
Bioorg Med Chem Lett; 1998 Feb; 8(3):267-72. PubMed ID: 9871667
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.
Armstrong JL; Taylor GA; Thomas HD; Boddy AV; Redfern CP; Veal GJ
Br J Cancer; 2007 Jun; 96(11):1675-83. PubMed ID: 17486130
[TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
[TBL] [Abstract][Full Text] [Related]
19. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells.
Sonneveld E; van den Brink CE; van der Leede BM; Schulkes RK; Petkovich M; van der Burg B; van der Saag PT
Cell Growth Differ; 1998 Aug; 9(8):629-37. PubMed ID: 9716180
[TBL] [Abstract][Full Text] [Related]
20. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
